MDMA-Assisted Psychotherapy for PTSD: A Systematic Review of Randomized Control Trials
Journal of Psychoactive Drugs November 5, 2025 DOI: 10.1080/02791072.2025.2577308 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review Randomized Peer reviewed |
|---|---|
| Sample size | 280 |
| Population | Adults with posttraumatic stress disorder |
| Intervention | MDMA-assisted psychotherapy |
| Topics | MDMA Psychedelic-assisted therapy PTSD |
| Keywords | Placebo Randomized controlled trial Posttraumatic stress Clinical trial Mental health Clinical psychology Medline Relapse prevention Psychotherapist Research design |
| Citations | 4 |
| Key findings | Five of six randomized controlled trials found significantly greater PTSD symptom reduction with MDMA-assisted psychotherapy compared to placebo, with 41.7% to 85.7% of MDMA recipients no longer meeting PTSD criteria post-treatment versus 25.0% to 33.3% in placebo groups. |
Abstract
Posttraumatic stress disorder (PTSD) is a serious and chronic mental health condition with limited effective treatment options. 3,4-methylenedioxymethamphethamine (MDMA)-assisted psychotherapy (MDMA-AT) has shown promise in phase 2 and phase 3 clinical trials, with many research participants reporting significant reductions in PTSD symptoms. However, the Federal Drug Administration (FDA) recently voted against recommending MDMA-AT, citing concerns about its risk-benefit profile. This systematic review aimed to assess current evidence from randomized control trials (RCTs) on the safety and efficacy of MDMA-AT for adults with PTSD to determine if it warrants consideration for approval. Two articles identified were excluded from our analysis due to their recent retraction from publication. In total, seven RCTs were identified, including 280 adult participants with PTSD (160 received MDMA; 120 received placebo). Data were independently reviewed, focusing on PTSD symptom reduction and safety. Of the six studies included in the efficacy analysis, five (83.3%) found significantly improved PTSD symptoms in the MDMA groups compared to placebo groups. In addition, 41.7% to 85.7% of participants receiving MDMA-AT no longer met PTSD criteria post-treatment, compared to 25.0% to 33.3% reported for placebo groups. In addition, the treatment appeared well-tolerated. These findings support the potential of MDMA-AT as a viable treatment option for the symptoms of PTSD, though additional research with strict ethical oversight should inform FDA approval.